Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes

Table 2 Logistic regression analysis: variables determining the decision to prescribe PEGV with or without SSA therapy (dependent variable)

COVARIATES	OR (95% CI)	P
GH at baseline (μg/L)	1.015 (0.983-1.043)	1.047
IGF-I SDS at baseline	1.003 (0.999-1.007)	0.097
Δ IGF I^aSDS	1.446 (1.153-1.814)	0.001
Detectable adenoma at baseline ^b	13.757 (2.547-74.307)	0.002

Abbreviations: CI confidence intervals, OR odds ratios, PEGV pegvisomant, SSA somatostatin analogs.
^a SDS observed at diagnosis minus SDS observed at baseline.
^b Includes patients who had not had surgery and those who had undergone surgery but presented residual tumor at baseline.

ISSN: 1756-9966